Oncoinvent reports third quarter clinical progress in live investor update
Oncoinvent ASA holds a live webcast on October 28, 2026, to discuss company developments and clinical trial enrollment status for its ovarian cancer program.
Oncoinvent ASA is hosting a webcast today to detail the company's progress during the third quarter of 2026. The presentation features leadership including CEO Øystein Soug, CFO Ramzi Amri, and CMO Zuzana Jirakova Trnkova.
The biotech firm is developing an alpha-emitter radiopharmaceutical designed to treat cancer cells in the abdominal cavity post-surgery. Central to the update is the status of its phase 2 clinical trial involving patients with ovarian cancer.
According to the report, Oncoinvent reached a total enrollment of 71 patients by the end of the third quarter, with 16 new patients recruited during that period. The company continues to monitor its development pipeline as it navigates the current clinical phase.